Hematology (all articles) | Page 9 of 50 | Links Medicus Content Curation & Alerts in Medicine

Talquetamab, a bifunctional antibody, directs activated T cells to tumor. In this study, up to 70% of the patients with relapsed or refractory myeloma had a response to this agent. https://t.co/OJGHobKG0E pic.twitter.com/53soLSCepA

— NEJM (@NEJM) December 10, 2022

Single-arm P1/2 study | Glofitamab for relapsed or refractory diffuse Large B-Cell Lymphoma.

12 Dec, 2022 | 12:37h | UTC

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

Glofitamab, a bifunctional antibody, was given to 154 patients with relapsed or refractory DLBCL. Complete response occurred in 39%; most of these responses were ongoing at 12 months. Cytokine release syndrome was common. https://t.co/FWavXlkVXD pic.twitter.com/F4eyYja2E4

— NEJM (@NEJM) December 11, 2022

M-A | Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage.

9 Dec, 2022 | 13:17h | UTC

Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis – JAMA Network Open

Commentary on Twitter

Meta-analysis finds mostly successful DOAC reversal with 4F-PCC (77%), andexanet alfa (AA)(75%), and idarucizumab (82%) in patients with ICH. 4F-PCC and AA had comparable success in factor Xa inhibitor reversal, mortality, and thromboembolic outcomes. #OA https://t.co/aieJd9h5jo

— JAMA Network Open (@JAMANetworkOpen) November 4, 2022

Preliminary study suggests that Edoxaban is a safe alternative for preventing thromboembolism in pediatric patients with cardiac disease.

9 Dec, 2022 | 13:07h | UTC

Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Editorial: Advancing Anticoagulation for Children With Cardiac Disease – Journal of the American College of Cardiology

Commentary: Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease – ENNOBLE-ATE – American College of Cardiology

Cohort Study | Cutaneous involvement in catastrophic antiphospholipid syndrome.

8 Dec, 2022 | 12:53h | UTC

Cutaneous Involvement in Catastrophic Antiphospholipid Syndrome in a Multicenter Cohort of 65 Patients – JAMA Dermatology (free for a limited period)

Commentary on Twitter

In this cohort study, half of patients with catastrophic APS (CAPS) showed cutaneous involvement, with a spectrum of clinical presentations, including distal inflammatory edema. Skin biopsies confirmed diagnosis in all but 1 biopsied patient. https://t.co/lwBL3lyLxT

— JAMA Dermatology (@JAMADerm) December 7, 2022

RCT | Fostamatinib for the treatment of patients with primary immune thrombocytopenia.

7 Dec, 2022 | 14:18h | UTC

Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study – British Journal of Haematology

Review | AL Amyloidosis for Cardiologists.

6 Dec, 2022 | 13:36h | UTC

AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review – JACC: CardioOncology

RCT | Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis.

2 Dec, 2022 | 14:24h | UTC

Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis – NEJM Evidence

Commentary on Twitter

This #RCT examined the use of rivaroxaban to reduce risk of venous thromboembolism (VTE) in pts with non-cirrhotic chronic portal vein thrombosis (PVT). Daily rivaroxaban reduced incidence of VTE and did not increase major bleeding events. https://t.co/CbenUb8ZWz #LiverTwitter pic.twitter.com/bgN1QS171j

— NEJM Evidence (@NEJMEvidence) November 22, 2022

Joint consensus statement on the vaccination of adult and pediatric hematopoietic stem cell transplant recipients.

30 Nov, 2022 | 13:39h | UTC

Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: Prepared on behalf of the British society of blood and marrow transplantation and cellular therapy (BSBMTCT), the Children’s cancer and Leukaemia Group (CCLG), and British Infection Association (BIA) – Journal of Infection

Consensus Paper | Hematopoietic cell transplantation in the management of myelodysplastic syndrome.

29 Nov, 2022 | 14:11h | UTC

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines – Transplantation and Cellular Therapy

Cohort Study | Trends and risk factors for venous thromboembolism among hospitalized medical patients.

29 Nov, 2022 | 14:04h | UTC

Trends and Risk Factors for Venous Thromboembolism Among Hospitalized Medical Patients – JAMA Network Open

Commentary on Twitter

1.2% of hospitalized patients developed a hospital-associated venous thromboembolism (HA-VTE), slightly increasing from 2013-2016 (1.1-1.6%). 78% happened after discharge; HA-VTE were linked to higher risk of readmission and death. @KPDOR https://t.co/cB8VhY7k7X #OAResearch

— JAMA Network Open (@JAMANetworkOpen) November 21, 2022